Genenta Science S.p.A. Logo

Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):
US36870W1009
LEI:
Country:
United States of America
Address:
OLGETTINA, NO. 58, 20132 MILAN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CureVac N.V. Logo
Pioneering mRNA technology for prophylactic vaccines and novel cancer immunotherapies.
United States of America CVAC
CURIS INC Logo
Biotech developing innovative cancer therapeutics for hematologic malignancies.
United States of America CRIS
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
CYBIN INC. Logo
A clinical-stage firm engineering novel psychedelic drugs for depression and anxiety.
United States of America CYBN
Cyclerion Therapeutics, Inc. Logo
Developing personalized therapy for TRD with a biofeedback device and anesthetics.
United States of America CYCN
Cyfuse Biomedical K.K. Logo Japan 4892
CYTOKINETICS INC Logo
Late-stage biopharma developing muscle-modulating drugs for heart and neuromuscular diseases.
United States of America CYTK
CytoMed Therapeutics Ltd Logo
Develops off-the-shelf cell immunotherapies using γδ T cells & NK cells for cancer treatment.
United States of America GDTC
CytomX Therapeutics, Inc. Logo
Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.
United States of America CTMX
Daebonglsco.,Ltd Logo
Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.
South Korea 078140

Talk to a Data Expert

Have a question? We'll get back to you promptly.